Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 2Head and Neck Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Laryngeal Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × monalizumab × Clear all
NCT03822351 2024-10-08

COAST

MedImmune LLC

Phase 2 Completed
189 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

MedImmune LLC

Phase 2 Completed
84 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡